Inventiva S.A. (IVA)

3.4500 -0.0400 (-1.15%) 收市：04:00PM EDT

Inventiva S.A.

50 rue de Dijon
Daix 21121
France
33 3 80 44 75 00
https://www.inventivapharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 120

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jean Volatier	Deputy GM & CFO	無	無	1965
Ms. Alice Roudot-Ketelers Pharm.D.	Chief Operating Officer	無	無	1971
Mr. Eric Duranson L.L.M.	General Counsel	無	無	1974
Ms. Nathalie Harroy	Head of Human Resources	無	無	1967
Dr. Michael Cooreman	Chief Medical Officer	無	無	1958
Ms. Pascaline Clerc Ph.D.	Executive Vice President of Strategy & Corporate Affairs	無	無	1980

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

公司管治

截至 2024年5月1日 止，Inventiva S.A. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：8；股東權利：9；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。